A
Antonio Craxì
Researcher at University of Palermo
Publications - 699
Citations - 44773
Antonio Craxì is an academic researcher from University of Palermo. The author has contributed to research in topics: Hepatitis C & Cirrhosis. The author has an hindex of 86, co-authored 659 publications receiving 39463 citations. Previous affiliations of Antonio Craxì include University of Pavia & University of Paris-Sud.
Papers
More filters
Journal ArticleDOI
Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment
Harry L.A. Janssen,G. Gerken,Vicente Carreño,Patrick Marcellin,Nikolai V. Naoumov,Antonio Craxì,Helmer Ring-Larsen,George Kitis,Jan van Hattum,Richard A. de Vries,Peter Michielsen,Fiebo J.W. ten Kate,Wim C. J. Hop,Rudolf A. Heijtink,P. Honkoop,Solko W. Schalm +15 more
TL;DR: A low level of viral replication after 16 weeks of treatment, as indicated by serum HBV‐DNA values under 10 pg/mL, was found to be the only independent predictor of response during prolonged therapy, and the prolonged IFN‐α schedule was well tolerated in the large majority of patients.
Journal ArticleDOI
Interferon‐α for chronic hepatitis C: An analysis of pretreatment clinical predictors of response
Luigi Pagliaro,Antonio Craxì,Calogero Cammaá,Fabio Tinè,Vito Di Marco,Oreste Lo Iacono,Piero Luigi Almasio +6 more
TL;DR: In patients with C hepatitis, presence of cirrhosis and long disease duration predict low likelihood of response to interferon and the addition of virological features such as quantitation of viremia and hepatitis C virus genotypes may improve the ability to predict treatment outcomes.
Journal ArticleDOI
Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity
Anna Ludovica Fracanzani,Salvatore Petta,Rosa Lombardi,Giuseppina Pisano,Maurizio Russello,Dario Consonni,Vito Di Marco,Calogero Cammà,Laura Mensi,Paola Dongiovanni,Luca Valenti,Antonio Craxì,Silvia Fargion +12 more
TL;DR: Significantly lower proportions of patients with lean NAFLD had hypertension, diabetes, and metabolic syndrome more than overweight or obese patients with NA FLD (526 patients; 149 women; mean age, 49 ± 12 y), and significantly higher risk of diabetes (odds ratio, 11; 95% confidence interval [CI].
Journal ArticleDOI
Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C
Calogero Cammà,Salvatore Petta,Giuseppe Cabibbo,Matteo Ruggeri,Marco Enea,Raffaele Bruno,Vincenza Capursi,Antonio Gasbarrini,Alfredo Alberti,Antonio Craxì +9 more
TL;DR: In untreated G1 CHC patients age 50 years, TT with first‐generation protease inhibitors is cost‐effective compared with DT.
Journal ArticleDOI
Reliability of liver stiffness measurement in non‐alcoholic fatty liver disease: the effects of body mass index
TL;DR: Liver stiffness measurement using transient elastography is used to stage fibrosis in patients with liver disease, diagnostic reliability and the factors affecting its performance in Patients with non‐alcoholic fatty liver disease (NAFLD) are incompletely understood.